22Dec
Cadent Therapeutics Acquired by Novartis for Up to $770 Million
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
The Court’s decision in New Riegel Local School District Board of Education, et al. v. The Buehrer ...
Read More >
Mass shootings have become a tragic reality in the United States. Recent years have witnessed a numb...
Read More >
On May 21, the Securities and Exchange Commission (SEC) adopted amendments to its rules governing fi...
Read More >
Employers may soon be able to submit Component 2 data to the Equal Employment Opportunity Commission...
Read More >
On June 13, 2019 the Department of Health and Human Services, Department of Labor and Department of ...
Read More >
California Governor Gavin Newsom on Sept. 18 signed into law Assembly Bill 5, landmark legislation w...
Read More >